Protara Therapeutics (TARA) director awarded 31,000 stock options at $3.94 strike

Rhea-AI Filing Summary

Protara Therapeutics director Michael Edward Solomon received a stock option grant for 31,000 shares of Common Stock. The option has an exercise price of $3.94 per share and was granted as a Stock Option (Right to Buy). It vests in full on the first anniversary of the grant date, subject to his continued service on the Board, and will also vest in full upon a Change of Control. Following this award, he holds 31,000 option shares related to this grant, which expires on June 14, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Solomon Michael Edward

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 31,000 shares Exercise price: $3.94 per share Underlying shares: 31,000 shares +3 more

6 metrics

Option grant size 31,000 shares Stock Option (Right to Buy) granted to director

Exercise price $3.94 per share Stock option exercise price for Common Stock

Underlying shares 31,000 shares Common Stock underlying the option grant

Total options after grant 31,000 shares Total option shares held following transaction

Vesting schedule 1-year cliff vesting Vests in full on first anniversary of grant date

Expiration date June 14, 2036 Option term end date for this grant

Key Terms

Stock Option (Right to Buy), Change of Control, Annual Grant

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Change of Control financial

"will vest in full upon a Change of Control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

Annual Grant financial

"The shares subject to the Annual Grant will vest in full"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Solomon Michael Edward

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.94	06/15/2026		A		31,000		06/15/2027(1)	06/14/2036	Common Stock	31,000	$0	31,000	D

Explanation of Responses:

1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

	/s/ Mary Grendell, Attorney-in-fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Protara Therapeutics (TARA) director Michael Edward Solomon receive in this Form 4?

He received a stock option grant for 31,000 shares of Common Stock. This award is a compensation-related grant, providing the right to buy shares at a fixed exercise price over time.

What is the exercise price of the stock options granted to the TARA director?

The stock options carry an exercise price of $3.94 per share. This means he can purchase Protara Therapeutics Common Stock at $3.94 once the options are vested and exercisable.

When do Michael Edward Solomon’s Protara Therapeutics options vest?

The options vest in full on the first anniversary of the grant date. Vesting is contingent on his continuous service as a member of Protara Therapeutics’ Board through that date.

How does a Change of Control affect the TARA director’s option grant?

The options will vest in full upon a Change of Control. This provision accelerates vesting so the director’s entire 31,000-share option becomes fully vested if such a corporate event occurs.

When do the stock options granted to the Protara Therapeutics director expire?

The stock options expire on June 14, 2036. After this expiration date, the director can no longer exercise the options to purchase Protara Therapeutics Common Stock at the stated exercise price.

How many option shares does the TARA director hold after this transaction?

Following this grant, he holds 31,000 option shares related to this award. This figure reflects his total beneficial ownership of this specific Stock Option (Right to Buy) grant.